Scarica l'app Stockscreener
36.96
1.87%
-0.48
Precedente Chiudi:
$37.44
Aprire:
$37.34
Volume 24 ore:
90,352
Relative Volume:
0.09
Capitalizzazione di mercato:
$2.78B
Reddito:
-
Utile/perdita netta:
$-301.06M
Rapporto P/E:
-7.5893
EPS:
-4.87
Flusso di cassa netto:
$-248.01M
1 W Prestazione:
+0.52%
1M Prestazione:
+20.50%
6M Prestazione:
-14.52%
1 anno Prestazione:
+73.71%
Intervallo 1D:
$36.43
$37.55
Intervallo di 1 settimana:
$34.29
$38.58
Portata 52W:
$20.19
$53.92
Springworks Therapeutics Inc Stock (SWTX) Company Profile
Nome
Springworks Therapeutics Inc
Settore
Industria
Telefono
203-883-9490
Indirizzo
100 WASHINGTON BOULEVARD, STAMFORD, CT
Confronta SWTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| SWTX | 37.03 | 2.78B | 0 | -301.06M | -248.01M | -4.87 |
| VRTX | 447.05 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.71 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.15 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.84 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.36 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-05 | Iniziato | Guggenheim | Buy |
| 2022-12-01 | Iniziato | BofA Securities | Buy |
| 2021-01-19 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2020-03-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-01-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2019-10-08 | Iniziato | Cowen | Outperform |
| 2019-10-08 | Iniziato | Goldman | Buy |
| 2019-10-08 | Iniziato | JP Morgan | Overweight |
| 2019-10-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Springworks Therapeutics Inc Borsa (SWTX) Ultime notizie
SpringWorks started at outperform by Evercore ahead of FDA decision - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Now Covered by Evercore ISI - MarketBeat
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - MSN
Victory Capital Management Inc. Has $20.17 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics: Q3 Earnings Snapshot - AOL
Equities Analysts Set Expectations for SWTX FY2024 Earnings - Defense World
Wedbush Has Negative Forecast for SWTX FY2024 Earnings - Defense World
When (SWTX) Moves Investors should Listen - Stock Traders Daily
Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report - Yahoo Finance
Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results - Simply Wall St
FY2024 Earnings Forecast for SWTX Issued By HC Wainwright - MarketBeat
Wedbush Has Negative Outlook for SWTX FY2024 Earnings - MarketBeat
SpringWorks Therapeutics Inc (SWTX) Quarterly 10-Q Report - Quartzy
Los Angeles Capital Management LLC Boosts Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
HC Wainwright Issues Pessimistic Forecast for SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price - Defense World
SpringWorks Therapeutics (NASDAQ:SWTX) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Principal Financial Group Inc. Has $29.43 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highli - GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Down on Analyst Downgrade - Defense World
SpringWorks Therapeutics Q3 2024 Results Overview - TipRanks
SpringWorks Therapeutics Inc (SWTX) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
SpringWorks Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - XM
HC Wainwright Cuts SpringWorks Therapeutics (NASDAQ:SWTX) Price Target to $74.00 - MarketBeat
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference - The Manila Times
SpringWorks Therapeutics to Present at Jefferies London Healthcare Conference | SWTX Stock News - StockTitan
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
SpringWorks Therapeutics (SWTX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
SpringWorks Therapeutics’ mirdametinib shows efficacy in neurofibromatosis study - Yahoo Finance
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Bakersfield Californian
SOPHiA GENETICS (NASDAQ:SOPH) vs. SpringWorks Therapeutics (NASDAQ:SWTX) Financial Review - Defense World
Earnings To Watch: SpringWorks Therapeutics Inc (SWTX) Reports Q - GuruFocus.com
SpringWorks Therapeutics Announces Mirdametinib Data to be - GlobeNewswire
SpringWorks' Cancer Drug Shows Breakthrough 62% Response Rate, FDA Fast-Tracks Review | SWTX Stock News - StockTitan
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology - Quantisnow
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating - The Bakersfield Californian
SpringWorks Therapeutics Announces Publication of the - GlobeNewswire
SpringWorks' Mirdametinib Shows Breakthrough 52% Response Rate in NF1-PN Trial | SWTX Stock News - StockTitan
Creative Planning Takes $254,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics (SWTX) Set to Announce Earnings on Tuesday - Defense World
Fiera Capital Corp Lowers Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Earns Outperform Rating from Wedbush - Defense World
Brokerages Set SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Price Target at $68.50 - Defense World
SpringWorks Therapeutics Announces Long-Term Efficacy and - GlobeNewswire
SpringWorks' OGSIVEO Shows 75.8% Tumor Reduction in 4-Year Treatment Data | SWTX Stock News - StockTitan
What's Going On With Rare Diseases-Focused SpringWorks Therapeutics Stock Today? - MSN
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Mirae Asset Global Investments Co. Ltd. Buys 474 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics (SWTX) to Release Earnings on Tuesday - MarketBeat
SpringWorks Therapeutics to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - The Manila Times
Springworks Therapeutics Inc Azioni (SWTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):